High Neutrophils and Cancer: What’s the Connection?

Elevated neutrophil counts in cancer patients reflect a deep, two-way relationship between the most abundant white blood cells in your body and the tumors that exploit them. Tumors actively recruit neutrophils by pumping out chemical signals, and once those neutrophils arrive, many of them get reprogrammed to shield the tumor, feed it new blood vessels, and even help cancer cells spread to distant organs. The story is more complicated than “high neutrophils mean cancer,” though, because some neutrophils retain the ability to kill tumor cells directly. Understanding which side wins, and why, is one of the most active frontiers in cancer immunology.

How Tumors Call Neutrophils to the Scene

Your bone marrow constantly produces neutrophils, releasing them into the bloodstream where they circulate and respond to signals of trouble. In a healthy person, those signals come from infections or injuries. In someone with cancer, the tumor itself becomes a powerful source of recruitment signals. One of the main chemical messengers involved is CXCL8 (also known as IL-8), which binds to receptors called CXCR1 and CXCR2 on the surface of neutrophils. The interaction between CXCL8 and these receptors is critical for pulling neutrophils toward the tumor and into its surrounding environment.¹ In glioblastoma, one of the most aggressive brain cancers, researchers found that CXCL8 levels were significantly elevated in tumor tissue and that higher levels correlated with reduced survival and greater neutrophil infiltration.²

Tumors also produce G-CSF, a growth factor normally used therapeutically to boost white blood cell counts after chemotherapy. Some cancers hijack G-CSF production through the RAS signaling pathway, a molecular circuit that is mutated in many tumor types. In pancreatic cancer, for instance, activation of this pathway drives G-CSF expression and enhanced neutrophil recruitment into the tumor.³ Tumors that produce high levels of G-CSF tend to be more aggressive, harder to treat, and associated with worse outcomes.⁴ So when a blood test shows elevated neutrophils in a cancer patient, it may partly reflect the tumor actively manufacturing the signals that summon them.

Not All Tumor Neutrophils Are Alike

One of the key insights from the past fifteen years of research is that neutrophils inside tumors are not a single uniform population. They roughly split into two functional types. The first, sometimes labeled N1, are pro-inflammatory and can attack tumor cells. The second, labeled N2, are immunosuppressive and tend to help the tumor grow. This distinction maps loosely onto high-density and low-density neutrophils found in the blood.⁵

What determines which type a neutrophil becomes? A major factor is TGF-beta, a signaling molecule abundant in many tumors. Research in mouse models showed that TGF-beta within the tumor pushes neutrophils toward the pro-tumor N2 state. When researchers blocked TGF-beta, the neutrophils that arrived were more cytotoxic to cancer cells, produced stronger inflammatory responses, and helped activate immune T cells. In untreated tumors, by contrast, depleting neutrophils actually slowed tumor growth, confirming that the default neutrophil population in those tumors was helping the cancer.⁶ The tumor, in other words, reprograms the very immune cells that should be fighting it.

This polarization also involves metabolic changes. Under normal conditions, neutrophils burn glucose aerobically for energy. Inside the oxygen-starved, nutrient-poor tumor environment, they shift to altered forms of metabolism that support their immunosuppressive behavior and help the tumor progress.⁷ The tumor essentially feeds and rewires the neutrophils to serve its own purposes.

Helping Tumors Spread Through Sticky DNA Webs

Neutrophils have a dramatic defense mechanism called neutrophil extracellular traps, or NETs. In normal immune function, a neutrophil can eject strands of its own DNA outward like a web, trapping bacteria and other pathogens. In cancer, these sticky webs take on a sinister role. Circulating tumor cells, the stray cancer cells that break away from a primary tumor and drift through the bloodstream, can become physically trapped within NETs. Once snared, those cells are more likely to lodge in distant organs and start new tumors.

In mouse models, researchers demonstrated that NET formation in blood vessels led to trapping of lung cancer cells, which then produced more liver metastases within 48 hours and significantly more metastatic disease two weeks later. When the researchers broke down the NETs using DNase or blocked their formation with a neutrophil elastase inhibitor, metastasis dropped dramatically.⁸ Beyond just physically trapping tumor cells, NETs also promote the kind of tissue changes that make a new site hospitable to cancer, including triggering DNA damage and helping cancer cells shift into more mobile, invasive forms.⁹

Building the Pre-Metastatic Niche

Even before cancer cells arrive at a distant organ, neutrophils can prepare the ground for them. This concept, known as the pre-metastatic niche, describes how tumors condition faraway tissues to become welcoming environments for metastatic colonization. Neutrophils are among the most important architects of these niches, shaping them through immunosuppression, inflammation, new blood vessel formation, and remodeling of the structural tissue around them.¹⁰

In breast cancer mouse models, neutrophils were identified as the main component driving metastatic establishment in the lungs. When researchers blocked neutrophil recruitment to these distant sites, metastatic colonization dropped. The mechanism involved neutrophil-derived leukotrienes, lipid-based signaling molecules that selectively expanded the subset of cancer cells with the highest tumor-forming potential.¹¹ So the neutrophils are not just passive bystanders at distant sites. They actively select for the most dangerous cancer cells and give them a survival advantage.

Feeding Tumors New Blood Vessels

Growing tumors need blood supply, and neutrophils help provide it. One of their key contributions to tumor angiogenesis involves an enzyme called MMP-9, which breaks down the structural scaffolding around blood vessels and releases growth factors that stimulate new vessel formation. Tumor-recruited neutrophils deliver a form of MMP-9 that is particularly potent because it lacks a natural inhibitor that normally keeps the enzyme in check. Research directly linked these neutrophils and their uninhibited MMP-9 to the formation of new blood vessels that then serve as highways for tumor cell escape into the bloodstream.¹²

VEGF-A, one of the most powerful signals for blood vessel growth, also recruits a specialized subset of neutrophils that carry roughly ten times more MMP-9 than neutrophils responding to a standard inflammatory signal.¹³ Beyond MMP-9, pro-tumor neutrophils contribute to angiogenesis through multiple routes, including releasing VEGF-A themselves, producing TGF-beta and IL-8, and even deploying NETs that increase blood vessel permeability.¹⁴ The result is a vicious cycle: the tumor signals for neutrophils, the neutrophils build blood vessels that feed the tumor, and the better-fed tumor grows larger and signals for more neutrophils.

Suppressing the Immune System From Within

Perhaps the most damaging thing pro-tumor neutrophils do is weaken the immune response that should be fighting the cancer. Some of these cells function as myeloid-derived suppressor cells, a broader category of immature immune cells that directly shut down T cell activity. T cells, especially CD8+ killer T cells, are the immune system’s main weapon against cancer. When suppressor neutrophils block them, the tumor grows unchecked.¹⁵

This immunosuppressive activity has real clinical consequences. Cancer development is associated with profound changes in how neutrophils are produced and how they behave, and these changes can predict and interfere with the response to immune checkpoint inhibitors, the drugs that have revolutionized treatment for melanoma, lung cancer, and other tumor types. Neutrophil infiltration in tumors is linked to key features of resistance to these drugs.¹⁶ In other words, the same neutrophil-driven immunosuppression that shields the tumor from your natural defenses also shields it from some of the most powerful cancer drugs available. Researchers are actively investigating strategies to target this neutrophil-driven resistance, with the goal of combining neutrophil-blocking approaches with checkpoint inhibitors for better outcomes.¹⁷

When Neutrophils Fight Back Against Cancer

The relationship is not entirely one-sided. Under the right conditions, neutrophils are formidable cancer killers. Their anti-tumor arsenal includes reactive oxygen species that damage tumor cells, the ability to activate cytotoxic T cells, enzymes that directly destroy cancer tissue, and a process called trogoptosis.¹⁸

Trogoptosis is a particularly striking mechanism. When cancer cells are coated with therapeutic antibodies, neutrophils latch onto them and physically tear away chunks of their cell membrane. Researchers watching this in real time saw neutrophils form cup-like structures at the contact site, rip membrane fragments off the cancer cell, and ultimately cause the cancer cell to rupture and die. This “death by nibbling” was potent enough to kill antibody-coated breast cancer cells in laboratory conditions.¹⁹

Another line of research showed that a molecule called C5a, part of the complement system, can activate neutrophils to produce a chain reaction ending in massive oxidative damage to tumor cells, clearing multiple tumor types without even needing T cell involvement.²⁰ These findings explain why researchers talk about neutrophils as a double-edged sword. The challenge is figuring out how to tip the balance toward killing rather than helping.

The Neutrophil-to-Lymphocyte Ratio as a Practical Marker

One of the most accessible clinical tools to come from this research is the neutrophil-to-lymphocyte ratio (NLR), a simple calculation from a standard blood count. You divide the number of neutrophils by the number of lymphocytes. It costs nothing extra beyond the routine blood work that cancer patients already get. A large cross-sectional study using U.S. national health data found that people with the highest NLR (above 2.6) had about a 20 percent higher prevalence of cancer compared to people with the lowest ratios, even after adjusting for age, smoking, diabetes, and many other factors.²¹

Across multiple meta-analyses of various solid tumors, a cutoff value above roughly 3.0 has emerged as a useful threshold. An elevated NLR correlates with tumor size, disease stage, metastatic potential, and lymphatic invasion. It has also shown independent prognostic value for overall survival, cancer-free survival, and cancer-specific survival.²² This does not mean that a high NLR on your blood test means you have cancer. Infections, chronic inflammation, stress, and medications all raise neutrophils and can elevate the ratio. But for someone who already has cancer, tracking NLR over time can offer a window into how the disease is progressing and how well treatment is working.

High Neutrophils During Treatment Can Mean Different Things

Context matters enormously when interpreting neutrophil levels in cancer patients. Chemotherapy commonly destroys neutrophils along with cancer cells, leading to dangerously low counts called neutropenia. Doctors often prescribe G-CSF to bring those counts back up and prevent life-threatening infections. Bacteremia develops in roughly a quarter of patients who develop febrile neutropenia during treatment. So in the treatment setting, high neutrophils are sometimes the intended result of supportive care rather than a sign of tumor activity.

The paradox here is real. G-CSF saves lives by preventing fatal infections during chemotherapy, but research suggests that G-CSF can also promote tumor cell proliferation, tumor stem cell survival, and migration.⁴ This does not mean G-CSF support is a bad idea; the immediate risk of dying from infection without it far outweighs the theoretical concern. But it does mean oncologists are paying closer attention to the timing, duration, and dosing of growth factor support.

Targeting Neutrophils as a Cancer Treatment Strategy

The growing understanding of pro-tumor neutrophils has opened several avenues for therapeutic intervention. One of the most promising involves destroying NETs before they can trap tumor cells. In a mouse study, daily injection of nanoparticles coated with DNase I (an enzyme that chews up DNA) significantly reduced metastatic burden. A third of the treated mice had no detectable metastases at all, while every single control mouse developed them. Both the number and size of metastatic sites were significantly reduced.²³ More recently, researchers developed biomimetic liposomes that specifically home in on NETs and deliver DNase I directly to them, successfully suppressing colorectal cancer liver metastases in animal models.²⁴

Another strategy targets the CXCL8-CXCR1/2 signaling axis that recruits neutrophils to tumors in the first place. Blocking CXCR2 in a mouse model of pancreatic cancer prevented neutrophils from mobilizing from the bloodstream and improved responses to chemotherapy.²⁵ Interestingly, though, the mechanism may be more nuanced than simply keeping neutrophils out of the tumor. One study found that CXCR2 blockade slowed tumor growth but did not actually reduce the number of neutrophils infiltrating the tumor, suggesting the drug was changing neutrophil behavior rather than just blocking their entry.²⁶ Translating these approaches into human cancer therapy remains a promising but early-stage effort.²⁷

Reading Neutrophil Signatures From a Blood Draw

An emerging frontier involves profiling individual neutrophils from blood samples to identify cancer-specific signatures. Using single-cell RNA sequencing on blood from patients with triple-negative breast cancer, one of the most aggressive forms, researchers found that circulating neutrophils from these patients looked markedly different from those in healthy donors. The cancer patients’ neutrophils showed significantly increased expression of genes related to cell migration and cellular energy production compared with controls. This kind of “liquid biopsy” approach could eventually allow clinicians to detect cancer-related immune changes from a simple blood draw, though the technology remains in early research stages. The broader implication is that the altered neutrophils circulating in cancer patients are not just a side effect of the disease. They carry a molecular fingerprint of the tumor’s influence, detectable even far from the tumor itself.